로딩 중…
StockDiggingStockDigging

Maravai LifeSciences Holdings, Inc.

MRVI· NASDAQ
$6.97-4.13%
2026-09-18

Financials

Valuation Metrics

Maravai LifeSciences Holdings, Inc.'s Market Cap is $2.57B. At end of 2025 it was $471M. Ranked #1821 of 3,121 in US market (top 58%), #663 of 1,463 on NASDAQ (top 45%), #110 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 41%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$2.57B
Revenue$209M
Net Income$-77M
Total Assets$604M
Net Assets$205M
Employees415
Value
P/B12.56x
P/S12.31x
FCF Yield-1.37%
Profitability
ROE-37.82%
ROA-12.82%
Op. Margin46.02%
Revenue Growth-3.28%
Financial Health
Debt Ratio121.28%
Total Debt$177M
FCF$-35M
Cash$70M
Current Ratio4.05x
Performance
1Y Return142.01%
1M Return-3.46%
From 52W High-26.01%
1Y MDD-29.60%
Trading
Volume2,382,622 shares
Trading Value$17M
Per Share
EPS$-0.21
BPS$0.55

Company Info

CEO Bernd Brust
Employees 415
HQ San Diego, US

Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.